



**TORONTO'S DR. PAUL SANTERRE NAMED
2014 ERNEST C. MANNING PRINCIPAL AWARD WINNER**

Calgary, AB. (Sept. 23, 2014) – Dr. Paul Santerre of Toronto is this year's \$100 000 Ernest C. Manning Principal Award winner for developing surface modifying macromolecules, trademarked as Endexo™. Dr. Santerre will receive his prize at the Foundation's 33rd Innovation Awards Gala in Ottawa on Wednesday October 22nd.

Patients requiring blood transfusions, IV fluids or antibiotics receive their treatment through a peripheral inserted central catheter (PICC) which has empowered doctors to provide treatment, but often leads to thrombus, or blood clots - which can be deadly - due to adverse reactions to the catheter. Previous attempts to reduce clotting during fluid delivery have typically led to other complications for patients.

Dr. Santerre's pioneer approach utilizes surface modifying macromolecules as additives introduced during the PICC manufacturing process. His approach has demonstrated a significant reduction in clotting. After being integrated into the manufacturing process through a one-step, cost-effective method, the macromolecules are able to stabilize all surfaces of the device, inside and outside, effectively reducing the incidence of clotting at significantly lower costs than traditional methods and at greater success for patients.

The BioFlo PICC catheter, invented and marketed by AngioDynamics, is the first medical device to utilize the Endexo™ technology and has been on the market in Canada following Health Canada approval in 2011 and in the US following FDA approval in 2012. More recently, BioFlo ports and dialysis catheters have also been approved and are available on the market, with demonstrated reductions in thrombus of 96% and 90% respectively in blood loop contact studies.

Thousands of BioFlo catheters have now been sold, with the potential to reduce the clinical challenges to patients each year. Endexo™ is also being tested in dialysis circuits for treating end stage renal disease, including dialyzers and blood lines, anticipating improved quality of life for potentially hundreds of thousands of patients annually.

“The recognition of the Manning Foundation and its work during the celebration of this award is an occasion to take a sober look at where Canada could be if decision makers at the municipal, provincial and federal levels capitalize on the potential economic opportunities that exist in Canada now that this nation has built, over the past three decades, a country with one of the highest post graduate training ratios per capita, in the world,” says Dr. Santerre.

“With Canada generating 12% of its GDP from health care products and services, and the stock market growth showing returns of 25-30% in the health care sectors of developed and leading developing nations for the past few years, it not only makes economic sense that we put every resource possible towards entrepreneurship in health related areas, but it is incumbent upon us to do it with aggressive timelines, accountable milestones, and recognition of success when it is achieved,” he said.

“The Ernest C. Manning Awards Foundation is helping to build a culture of Canadian innovation by recognizing and rewarding Canadian innovators” says Foundation President Jennifer Diakiw. “Our Awards celebrate innovators who are improving the lives of Canadians and others around the world through their commercialized innovations. They add value to our provincial and national economies by creating jobs and wealth and positioning our country as a global competitor. Our distinguished alumni are leaders in technology, business, engineering, and social innovation advancement, and we consider them Canada's most valuable resource.”

For more information about the Foundation and the 33rd Ernest C. Manning Innovation Awards Gala visit www.manningawards.ca. Follow Manning Awards on Twitter @ManningAwardsCA, or like on Facebook at www.facebook.com/ManningAwards.